Naproxen vs Ibuprofen: Which Is Stronger and Safer
TL;DR
- Naproxen lasts 8–12 hours per dose versus 4–6 hours for ibuprofen, meaning fewer daily doses but a longer window for side effects.
- Neither drug is categorically "stronger" — milligram-for-milligram, ibuprofen and naproxen deliver comparable anti-inflammatory and analgesic effects at recommended doses, but naproxen carries roughly double the risk of upper gastrointestinal bleeding at OTC-equivalent doses.
- Cardiovascular event rates are broadly similar between the two in large randomized data, though some evidence suggests naproxen may have a modest advantage in patients not taking aspirin.
- Choosing between them depends on your pain pattern, dosing convenience, stomach history, and cardiovascular risk profile — a decision best made with your prescriber.
How Naproxen vs Ibuprofen Actually Compare: Pharmacology Basics
Naproxen and ibuprofen are both non-selective, non-steroidal anti-inflammatory drugs (NSAIDs) belonging to the propionic acid class. They work by inhibiting cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), the enzymes responsible for prostaglandin synthesis. Prostaglandins mediate inflammation, pain signaling, and fever — but they also protect the gastric mucosa and support renal perfusion, which is why blocking them comes with a predictable side-effect profile.
Despite sharing a mechanism, the two drugs differ in important pharmacokinetic parameters. Naproxen sodium (Aleve) has an elimination half-life of 12–17 hours, allowing twice-daily dosing. Ibuprofen (Advil, Motrin) has a much shorter half-life of roughly 2–4 hours, requiring dosing every 4–6 hours for sustained effect. This single difference shapes much of the clinical decision-making around these agents.
Both are well absorbed orally, with peak plasma concentrations reached in 1–2 hours for ibuprofen and 1–4 hours for naproxen sodium. Both are highly protein-bound (>99% for naproxen, ~99% for ibuprofen), extensively hepatically metabolized, and renally excreted as inactive metabolites.
From a regulatory standpoint, the U.S. FDA and the U.K. NICE both classify naproxen and ibuprofen as first-line OTC analgesics for mild-to-moderate musculoskeletal pain, dysmenorrhea, headache, and fever [VERIFY]. The FDA's 2015 strengthened warning applies equally to all non-aspirin NSAIDs, requiring boxed warnings for cardiovascular thrombotic events and gastrointestinal bleeding [VERIFY].
Potency and Efficacy: Is One a Stronger NSAID?
The word "stronger" is misleading when comparing naproxen or ibuprofen, because analgesic potency depends on the dose, the condition being treated, and the outcome measured.
At standard OTC doses — naproxen sodium 220 mg every 8–12 hours (maximum 660 mg/day) versus ibuprofen 200–400 mg every 4–6 hours (maximum 1200 mg/day OTC) — the analgesic effect is clinically equivalent for most acute pain conditions. Cochrane systematic reviews of single-dose postoperative pain trials find that both drugs achieve roughly 50% pain relief in about half of patients at standard OTC doses, with overlapping confidence intervals [VERIFY].
At full prescription doses — naproxen 500 mg twice daily (1000 mg/day) versus ibuprofen 800 mg three times daily (2400 mg/day) — anti-inflammatory efficacy is again comparable for osteoarthritis and rheumatoid arthritis. The PRECISION trial, which randomized over 24,000 arthritis patients to celecoxib, naproxen (mean daily dose 852 ± 103 mg), or ibuprofen (mean daily dose 2045 ± 246 mg), used these drugs at therapeutic anti-inflammatory doses and found broadly similar efficacy across all three arms for arthritis symptom control [1].
Where naproxen has a practical advantage is convenience. Its long half-life means patients take one or two tablets per day rather than three to six, which improves adherence. For chronic conditions such as ankylosing spondylitis or menstrual pain that persists through the night, naproxen's sustained action can translate into better overnight coverage.
For acute, short-lived pain — a tension headache, a mild sports strain — ibuprofen's rapid onset and shorter duration may be preferable, because it clears the body faster and limits cumulative COX inhibition.
OTC and Prescription Dosing Comparison
| Parameter | Naproxen sodium (Aleve) | Ibuprofen (Advil, Motrin) |
|---|---|---|
| OTC single dose | 220 mg | 200–400 mg |
| OTC maximum daily dose | 660 mg (3 tablets) | 1200 mg (3–6 tablets) |
| Prescription single dose | 250–500 mg | 400–800 mg |
| Prescription max daily dose | 1000–1500 mg | 2400–3200 mg |
| Dosing interval | Every 8–12 hours | Every 4–6 hours |
| Onset of action | 30–60 minutes | 20–30 minutes |
| Duration of action | 8–12 hours | 4–6 hours |
| Elimination half-life | 12–17 hours | 2–4 hours |
| Available OTC (U.S.) | Yes | Yes |
| Available OTC (U.K.) | Yes (limited pack size) | Yes |
A practical note: the OTC formulation of naproxen in the United States is naproxen sodium, which is absorbed slightly faster than naproxen base (the prescription form, e.g., Naprosyn). The 220 mg naproxen sodium tablet delivers 200 mg of naproxen free acid. This distinction matters little clinically but occasionally confuses dose comparisons.
Cardiovascular Safety: Aleve vs Advil and the PRECISION Data
Cardiovascular risk is the headline concern with any NSAID. All non-aspirin NSAIDs carry an FDA-mandated boxed warning for increased risk of major adverse cardiovascular events (MACE), including myocardial infarction and stroke [VERIFY].
For years, observational data suggested that naproxen might be the cardiovascular-friendliest NSAID, possibly because its long-duration COX-1 inhibition mimics low-dose aspirin's antiplatelet effect. The PRECISION trial — the largest randomized, double-blind cardiovascular safety trial ever conducted for NSAIDs — tested this hypothesis directly [1].
In PRECISION, 24,081 patients with osteoarthritis or rheumatoid arthritis and established cardiovascular disease or cardiovascular risk factors were randomized to celecoxib (mean dose 209 ± 37 mg/day), naproxen (852 ± 103 mg/day), or ibuprofen (2045 ± 246 mg/day). The primary composite outcome was cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke [1].
Key findings from the intention-to-treat analysis:
- Primary MACE events occurred in 2.3% of the celecoxib group, 2.5% of the naproxen group, and 2.7% of the ibuprofen group [1].
- Celecoxib met noninferiority criteria compared with both naproxen and ibuprofen.
- Ibuprofen showed a numerically higher rate of cardiovascular events than naproxen, but the difference was not statistically significant in the intention-to-treat population [1].
A secondary analysis from PRECISION examining cardiorenal outcomes — a composite of adjudicated renal events, hospitalization for congestive heart failure, or hospitalization for hypertension — found that ibuprofen was associated with significantly more cardiorenal events than celecoxib, while naproxen fell in between [2]. The cardiorenal composite event rate was meaningfully higher with ibuprofen than with naproxen in the on-treatment analysis [2].
A further pre-specified subgroup analysis examined the effect of concomitant low-dose aspirin. Among patients not taking aspirin, both naproxen and ibuprofen were associated with greater risk for the primary composite endpoint compared with celecoxib. When aspirin was coadministered, the difference between naproxen and celecoxib was attenuated, though ibuprofen continued to show higher composite event rates [5].
Clinical interpretation: The PRECISION data do not confirm the long-held assumption that naproxen is substantially cardioprotective relative to other NSAIDs. The differences in cardiovascular event rates between naproxen and ibuprofen are small and mostly nonsignificant. However, ibuprofen's slightly worse cardiorenal profile — particularly regarding blood pressure elevation and heart failure hospitalization — is a consideration for patients with existing cardiovascular disease [2].
NICE guidance (CG177) advises prescribing the lowest effective NSAID dose for the shortest possible duration and exercising particular caution in patients with cardiovascular risk factors [VERIFY]. The FDA's position is consistent: no non-aspirin NSAID has proven cardiovascular safety, and the risk increases with dose and duration [VERIFY].
Gastrointestinal and Renal Adverse Effects: Safety Table
Gastrointestinal toxicity is the most common serious adverse effect of both drugs, and this is where the naproxen vs ibuprofen comparison becomes clinically important.
A large claims-database study (Strom et al., 1997) compared over 100,000 naproxen sodium users with nearly 280,000 ibuprofen users at doses approximating OTC use. The incidence of upper gastrointestinal bleeding (UGIB) requiring hospitalization within 14 days of the first prescription was 0.026% for naproxen sodium versus 0.012% for ibuprofen — an adjusted relative risk of 2.0 (95% CI 1.1–3.8) [3]. Among patients receiving multiple prescriptions at typical OTC doses, the crude relative risk rose to 4.1 (95% CI 1.2–13.8) [3].
The SOS Project, a systematic review and meta-analysis of 59 observational studies, evaluated the relative risk of upper gastrointestinal complications for individual NSAIDs compared with non-use. Ibuprofen had one of the lowest pooled relative risks (approximately 1.8–2.0), while naproxen's pooled relative risk was notably higher (approximately 3.0–4.0), placing it in the intermediate-risk tier alongside other longer-acting NSAIDs [4].
In the PRECISION trial, gastrointestinal events (including bleeding, obstruction, perforation, and clinically significant anemia due to GI blood loss) occurred more frequently in the naproxen group than in the celecoxib group, with ibuprofen falling between the two in the on-treatment analysis [1]. Additionally, acute pancreatitis — a rarer but serious complication — was evaluated in a subsidiary PRECISION analysis and found at low rates across all three arms [6].
| Adverse Effect | Naproxen | Ibuprofen | Recommended Action |
|---|---|---|---|
| Upper GI bleeding (OTC doses) | ~0.026% incidence; RR ≈ 2.0 vs ibuprofen [3] | ~0.012% incidence (reference) [3] | Use lowest dose, shortest duration; add PPI if risk factors present |
| Upper GI complications (pooled RR vs non-use) | RR ≈ 3.0–4.0 [4] | RR ≈ 1.8–2.0 [4] | Avoid in patients with prior GI ulcer/bleed; co-prescribe PPI |
| Cardiovascular MACE | 2.5% (PRECISION ITT) [1] | 2.7% (PRECISION ITT) [1] | Avoid prolonged use in patients with established CVD |
| Cardiorenal composite (CHF, HTN, renal) | Intermediate risk [2] | Higher risk [2] | Monitor blood pressure and renal function; avoid in CKD stage ≥3 |
| Blood pressure elevation | Modest | More pronounced [2] | Monitor BP within 2–4 weeks of initiation |
| Hepatotoxicity | Rare (<1%) | Rare (<1%) | Check LFTs if symptomatic; discontinue if transaminases >3× ULN |
| Acute pancreatitis | Very rare [6] | Very rare [6] | Discontinue NSAID; evaluate alternative causes |
| Platelet inhibition | Sustained (12+ hours) | Brief (hours) | May interfere with low-dose aspirin timing (ibuprofen specifically) |
Red flags — seek immediate medical attention:
- Black, tarry stools or hematemesis (GI bleeding)
- Chest pain, sudden weakness, or slurred speech (cardiovascular event)
- Significant edema, rapid weight gain, or decreased urine output (renal/cardiac decompensation)
- Severe abdominal pain radiating to the back (pancreatitis)
- Allergic reaction: rash, facial swelling, bronchospasm
Special Populations and Clinical Pearls
Pregnancy and lactation
Both naproxen and ibuprofen are generally avoided during pregnancy. The FDA issued a strengthened warning in 2020 against NSAID use at 20 weeks gestation or later due to the risk of fetal renal dysfunction and oligohydramnios [VERIFY]. In the third trimester, all NSAIDs risk premature closure of the ductus arteriosus. ACOG advises against routine NSAID use after 20 weeks, with particular caution after 30 weeks [VERIFY].
During the first trimester, short-term ibuprofen use is sometimes considered acceptable for specific indications when paracetamol (acetaminophen) is insufficient, though data are limited. Naproxen, with its longer half-life and greater fetal exposure window, is generally less preferred [VERIFY].
In breastfeeding, ibuprofen is considered compatible with lactation by the AAP and is a preferred analgesic for nursing mothers due to minimal transfer into breast milk and its short half-life. Naproxen enters breast milk in small amounts, and its long half-life raises theoretical concerns about accumulation in the neonate; it is generally considered an alternative rather than first-line choice during breastfeeding [VERIFY].
Pediatric use
Ibuprofen is approved for OTC use in children aged 6 months and older (at doses of 5–10 mg/kg every 6–8 hours) and is the most widely studied NSAID in pediatrics. Naproxen is approved for children aged 2 years and older for juvenile idiopathic arthritis (prescription only, 5–7 mg/kg twice daily) but is not routinely recommended as a first-line OTC analgesic in young children [VERIFY].
Elderly patients
Both drugs pose increased GI and renal risk in patients over 65. NICE and the American Geriatrics Society Beers Criteria recommend avoiding chronic NSAID use in elderly patients when possible [VERIFY]. If an NSAID is necessary, the lowest effective dose for the shortest period is paramount. Co-prescription of a proton pump inhibitor (PPI) is recommended for elderly patients who require NSAID therapy beyond a few days.
Aspirin interaction
This is an often-overlooked clinical pearl. Ibuprofen can interfere with the antiplatelet effect of low-dose aspirin if taken before or concurrently. The FDA advises taking ibuprofen at least 30 minutes after or 8 hours before immediate-release aspirin to avoid this interaction [VERIFY]. Naproxen may also interact with aspirin, but the clinical significance appears less pronounced due to naproxen's own sustained COX-1 inhibition. In the PRECISION subgroup analysis, the safety profile of NSAIDs shifted depending on aspirin co-use, with ibuprofen showing less favorable outcomes than celecoxib among aspirin users [5].
Renal impairment
Both agents should be avoided or used with extreme caution in patients with an eGFR below 30 mL/min. NICE recommends avoiding all NSAIDs in patients with severe chronic kidney disease [VERIFY]. For patients with mild-to-moderate renal impairment, ibuprofen's shorter half-life means a briefer window of COX inhibition in the kidney, which is a theoretical advantage, though clinical evidence of meaningful difference in renal outcomes between the two is limited.
When to choose naproxen
- Chronic pain requiring all-day coverage (e.g., inflammatory arthritis, chronic low back pain)
- When twice-daily dosing improves adherence
- When low-dose aspirin is being taken (less pharmacodynamic interference)
When to choose ibuprofen
- Acute, short-duration pain (headache, dental pain, minor injury)
- Patients at higher GI risk who need only brief NSAID use
- Pediatric fever or pain
- Breastfeeding mothers
- When faster onset and faster clearance are desirable
FAQ
Q1: Is Aleve stronger than Advil? A1: Not in a pharmacological sense. At their respective recommended OTC doses, naproxen sodium 220 mg (Aleve) and ibuprofen 200–400 mg (Advil) produce similar levels of pain relief and anti-inflammatory effect. Naproxen simply lasts longer per dose — 8 to 12 hours versus 4 to 6 hours for ibuprofen. This extended duration can feel "stronger" because a single dose covers more of the day, but on a dose-for-dose basis, the drugs are comparably effective.
Q2: Which is safer for the stomach — naproxen or ibuprofen? A2: Ibuprofen has a lower risk of upper gastrointestinal bleeding than naproxen at typical OTC doses. A large database study found that naproxen sodium carried roughly twice the adjusted relative risk of GI bleeding requiring hospitalization compared with ibuprofen [3]. The SOS meta-analysis confirmed ibuprofen's relatively lower GI risk among common NSAIDs [4]. If you have a history of stomach ulcers or GI bleeding, ibuprofen (at the lowest dose, shortest duration) is generally the safer choice — or better yet, discuss alternatives with your doctor.
Q3: Can I switch between naproxen and ibuprofen? A3: You should not take both simultaneously, as combining two NSAIDs increases the risk of GI bleeding and renal injury without added benefit. If you want to switch from one to the other, allow the previous drug to clear. A practical approach: wait at least 12 hours after the last naproxen dose (given its long half-life) or 6–8 hours after the last ibuprofen dose before taking the other. As always, consult your pharmacist or physician before switching.
Q4: Is naproxen better for heart health than ibuprofen? A4: Earlier observational studies suggested naproxen might be the most "cardio-friendly" NSAID, but the large PRECISION randomized trial showed no statistically significant difference in major cardiovascular events between naproxen and ibuprofen in the intention-to-treat analysis [1]. However, ibuprofen was associated with more cardiorenal events — particularly blood pressure elevation and heart failure hospitalization — in secondary analyses [2]. Neither drug should be considered safe for the heart, especially with long-term use. The FDA warns that all non-aspirin NSAIDs increase cardiovascular risk.
Q5: How long can I safely take naproxen or ibuprofen over the counter? A5: The FDA-approved OTC labeling advises using these drugs for no more than 10 consecutive days for pain (or 3 days for fever) unless directed by a physician. NICE similarly recommends the shortest possible duration. Chronic use — even at OTC doses — increases the risk of GI bleeding, cardiovascular events, and renal injury. If you find yourself reaching for an NSAID daily, schedule a visit with your healthcare provider to investigate the underlying cause and explore safer long-term management strategies.
References
[1] Nissen SE, Yeomans ND, Solomon DH et al. The New England Journal of Medicine 2016. PMID:27959716. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis
[2] Obeid S, Libby P, Husni E et al. European Heart Journal – Cardiovascular Pharmacotherapy 2022. PMID:35234840. Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial
[3] Strom BL, Schinnar R, Bilker WB et al. Archives of Internal Medicine 1997. PMID:9531232. Gastrointestinal tract bleeding associated with naproxen sodium vs ibuprofen
[4] Castellsague J, Riera-Guardia N, Calingaert B et al. Drug Safety 2012. PMID:23137151. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project)
[5] Reed GW, Abdallah MS, Shao M et al. Journal of the American College of Cardiology 2018. PMID:29673465. Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen
[6] Yeomans ND, Graham DY, Wang Q et al. The American Journal of Gastroenterology 2018. PMID:29535414. Acute pancreatitis with long-term celecoxib vs. ibuprofen or naproxen: data from the PRECISION trial
About the author
Dr. Stanislav Ozarchuk, PharmD, has 15 years of clinical pharmacy experience. He writes for PillsCard.com, the international drug encyclopedia.
Medical disclaimer
The information provided here is for educational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.